MCID: PST005
MIFTS: 54

Posterior Uveitis

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Posterior Uveitis

MalaCards integrated aliases for Posterior Uveitis:

Name: Posterior Uveitis 12 74 20 58 15 17
Uveitis, Posterior 12 74 44 71
Uveitis Posterior 54
Choroiditis 58

Characteristics:

Orphanet epidemiological data:

58
posterior uveitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12574
MeSH 44 D015866
NCIt 50 C35111
SNOMED-CT 67 46627006
ICD10 via Orphanet 33 H30.0 H30.1 H30.2 more
UMLS via Orphanet 72 C0008526 C0042167
Orphanet 58 ORPHA280892
UMLS 71 C0042167

Summaries for Posterior Uveitis

MalaCards based summary : Posterior Uveitis, also known as uveitis, posterior, is related to choroiditis and chorioretinitis, and has symptoms including eye manifestations An important gene associated with Posterior Uveitis is IL2RA (Interleukin 2 Receptor Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Prednisolone and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are growth/size/body region and hematopoietic system

Wikipedia : 74 Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the... more...

Related Diseases for Posterior Uveitis

Diseases in the Uveitis family:

Autoimmune Uveitis Posterior Uveitis
Intermediate Uveitis Infectious Anterior Uveitis
Infectious Posterior Uveitis Systemic Diseases with Anterior Uveitis
Systemic Diseases with Posterior Uveitis

Diseases related to Posterior Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 744)
# Related Disease Score Top Affiliating Genes
1 choroiditis 31.5 TNF SAG RBP3 IFNG CFH
2 chorioretinitis 31.3 TNF SAG RBP3 IL6 IL2 IFNG
3 retinal vasculitis 31.2 TNF SAG RBP3 CCR6
4 macular retinal edema 31.1 TNF IL6 CFH
5 multifocal choroiditis 31.1 TNF CFH
6 iridocyclitis 31.0 TNF RBP3 IL6
7 retinal detachment 30.8 TNF IL6 IFNG CAPN5
8 neuroretinitis 30.6 SAG CAPN5
9 toxoplasmosis 30.6 TNF IL6 IL5 IL4 IFNG
10 sympathetic ophthalmia 30.5 TNF RBP3 LTA
11 optic neuritis 30.4 TNF LTA IL6
12 lyme disease 30.4 TNF IL6 CFH
13 endophthalmitis 30.2 TNF SAG IL6
14 fuchs' heterochromic uveitis 30.2 IL6 IFNG
15 neuritis 30.2 TNF LTA IL6 IL4 IFNG
16 intermediate uveitis 30.2 TNF IL6 IL2RA IL2 IFNG CCR6
17 pars planitis 30.1 RBP3 IL2 IL1A CCR6
18 hypopyon 30.0 TNF RBP3 IL6
19 measles 30.0 TNF IL6 IL2RA IL2 IFNG
20 chronic graft versus host disease 30.0 IL2RA IL1A IFNG
21 mumps 30.0 TNF IL6 IL2 IFNG
22 cardiac sarcoidosis 30.0 TNF IL5 IFNG
23 lymphopenia 30.0 IL6 IL4 IL2RA IL2 IFNG
24 hepatitis a 29.9 TNF IL4 IFNG
25 toxocariasis 29.9 IL5 IL4 IL13
26 eales disease 29.9 TNF SAG RBP3 IL6 IL4 IFNG
27 keratopathy 29.9 TNF IL4 IL1A
28 mycobacterium tuberculosis 1 29.8 TNF IL4 IFNG ICOSLG CCR6
29 uveitis 29.8 TNF SAG RBP3 LTA IL9 IL6
30 severe acute respiratory syndrome 29.8 TNF IL6 IFNG
31 panuveitis 29.8 TNF SAG RBP3 IL6 ICOSLG CCR6
32 myocarditis 29.8 TNF IL6 IL4 IL2 IFNG
33 autoimmune uveitis 29.7 TNF SAG RBP3 IL4 IL2 IFNG
34 cytokine deficiency 29.7 IL9 IL5 IL13
35 scleritis 29.7 TNF IL5 IL4 IFNG CCR6
36 vascular disease 29.7 TNF IL6 IL2 IL1A IFNG
37 lichen planus 29.6 TNF IL6 IL4 IL2 IFNG
38 optic nerve disease 29.6 TNF IL6 ICOSLG CCR6
39 rheumatic fever 29.6 TNF IL6 IL2 IL1A IFNG
40 graft-versus-host disease 29.6 TNF IL6 IL2 IL1A IFNG
41 cryptococcosis 29.6 TNF IL4 IL13 IFNG CCR6
42 proteasome-associated autoinflammatory syndrome 1 29.6 TNF IL6 IL5 IL4 IL1A IL13
43 pulmonary tuberculosis 29.6 TNF IL6 IL4 IL2RA IL2 IFNG
44 pneumocystosis 29.6 TNF IL6 IL2 CCR6
45 osteomyelitis 29.6 TNF IL6 IL4 IL1A IFNG
46 central nervous system lymphoma 29.6 IL6 IL2 CCR6
47 iritis 29.5 TNF RBP3 IL6 CCR6
48 histoplasmosis 29.5 TNF IFNG CFH CCR6
49 leptospirosis 29.5 TNF IL6 IL4 IL2 IL1A IFNG
50 erythema nodosum 29.5 TNF LTA IL6 IL1A IL13 IFNG

Graphical network of the top 20 diseases related to Posterior Uveitis:



Diseases related to Posterior Uveitis

Symptoms & Phenotypes for Posterior Uveitis

UMLS symptoms related to Posterior Uveitis:


eye manifestations

MGI Mouse Phenotypes related to Posterior Uveitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 CAPN5 CFH IFNG IL13 IL2 IL2RA
2 hematopoietic system MP:0005397 10.24 CCR6 CFH IFNG IL13 IL1A IL2
3 homeostasis/metabolism MP:0005376 10.2 CCR6 CFH IFNG IL13 IL1A IL2
4 immune system MP:0005387 10.16 CAPN5 CCR6 CFH IFNG IL13 IL1A
5 digestive/alimentary MP:0005381 10.09 IFNG IL13 IL2 IL2RA IL4 IL5
6 liver/biliary system MP:0005370 9.76 IFNG IL2 IL2RB IL4 IL5 IL6
7 respiratory system MP:0005388 9.61 IFNG IL13 IL2 IL2RA IL4 IL5
8 vision/eye MP:0005391 9.36 CFH IFNG IL2 IL2RA IL4 IL6

Drugs & Therapeutics for Posterior Uveitis

Drugs for Posterior Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 264)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
2 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7
Iodine Approved, Investigational Phase 4 7553-56-2 807
8
Lactitol Approved, Investigational Phase 4 585-86-4 157355
9
Povidone-iodine Approved Phase 4 25655-41-8
10
Povidone Approved Phase 4 9003-39-8 131751496
11
Ofloxacin Approved Phase 4 82419-36-1 4583
12
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
13
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
14
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
15
Travoprost Approved Phase 4 157283-68-6 5282226
16
Clonidine Approved Phase 4 4205-90-7 2803
17
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
18
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
19
Brinzolamide Approved Phase 4 138890-62-7 68844
20
Timolol Approved Phase 4 26839-75-8 33624 5478
21
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
22
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
23
Empagliflozin Approved Phase 4 864070-44-0
24
Dipivefrin Approved Phase 4 52365-63-6 3105
25
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
26
Bevacizumab Approved, Investigational Phase 4 216974-75-3
27
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
28
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
29
Cadexomer iodine Experimental Phase 4 94820-09-4
30
Maleic acid Experimental Phase 4 110-16-7 444266
31 Methylprednisolone Acetate Phase 4
32 Pharmaceutical Solutions Phase 4
33 Adrenergic alpha-Agonists Phase 4
34 Respiratory System Agents Phase 4
35 Neurotransmitter Agents Phase 4
36 Antihypertensive Agents Phase 4
37 Mydriatics Phase 4
38 Adrenergic Agents Phase 4
39 Adrenergic Agonists Phase 4
40 Parasympatholytics Phase 4
41 Anti-Asthmatic Agents Phase 4
42 Cholinergic Antagonists Phase 4
43 Muscarinic Antagonists Phase 4
44 Bronchodilator Agents Phase 4
45 Cholinergic Agents Phase 4
46 Anti-Arrhythmia Agents Phase 4
47 Brimonidine Tartrate Phase 4 70359-46-5
48 Adrenergic Antagonists Phase 4
49 Adrenergic beta-Antagonists Phase 4
50 Carbonic Anhydrase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 425)
# Name Status NCT ID Phase Drugs
1 A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
2 The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study Unknown status NCT01306955 Phase 4 methylorednisolone
3 Open-label, Non-randomized, Unmasked, Study of IAI in Patients Which Choroidal Neovascularization Secondary to Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
4 Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis. Unknown status NCT01669447 Phase 4
5 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
6 Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
7 The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT03159884 Phase 4 Conbercept
8 Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy Unknown status NCT03244657 Phase 4 conbercept ophthalmic injection (0.5mg);conbercept ophthalmic injection (0.5mg)
9 Multicenter Randomized Controlled Study of Intravitreal Ranibizumab and Triamcinolone Acetonide Combination Therapy Versus Ranibizumab Monotherapy in Patients With Polypoidal Choroidal Vasculopathy Unknown status NCT02806752 Phase 4 Triamcinolone Acetonide;Ranibizumab
10 A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma Unknown status NCT00540930 Phase 4 Ranibizumab
11 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
12 Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy Completed NCT02049476 Phase 4 Dexamethasone pellet
13 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
14 A Randomised Controlled Trial of Epimacular Brachytherapy Versus Ranibizumab Monotherapy for the Treatment of Subfoveal Choroidal Neovascularisation Associated With Wet Age-related Macular Degeneration in Patients Who Have Commenced Anti-VEGF Therapy Completed NCT01006538 Phase 4 Ranibizumab
15 A Phase IV, Randomised, Single Masked Study Investigating the Efficacy and Safety of Ranibizumab "Inject and Extend" Using an Intensive Retinal Fluid Retreatment Regimen Compared to a Relaxed Retinal Fluid Retreatment Regimen in Patients With Wet Age-related Macular Degeneration (AMD) Completed NCT01972789 Phase 4 Ranibizumab
16 Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation Completed NCT01871376 Phase 4 Intravitreal aflibercept injection 2.0mg
17 Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV) Completed NCT02860858 Phase 4
18 Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy Completed NCT02072408 Phase 4 aflibercept
19 A Multicentre, Randomized, Double Masked, Exploratory, Indocyanine Green Angiography (ICGA) Guided Study of 6 Months Duration to Compare the Safety and Effect on Polyp Regression of Verteporfin Photodynamic Therapy (PDT) Alone or Added to Ranibizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed NCT00674323 Phase 4 Verteporfin Photodynamic Therapy;Ranibizumab
20 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
21 Time Course of Activity Signs at High Resolution OCT During OCT-guided High Frequency Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Age Related Macular Degeneration Completed NCT03393767 Phase 4 Ranibizumab
22 Dosing Strategy of Intravitreal Ranibizumab for Myopia Choroidal Neovascularization: a Single Center Randomized Prospective Study Completed NCT03042871 Phase 4 0.5mg intravitreal ranibizumab
23 A Phase IV, Long-term, Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) Completed NCT00504959 Phase 4 ranibizumab
24 Efficacy and Safety of Initial Versus Delayed Verteporfin Photodynamic Therapy in Combination With Conbercept in Patients With Symptomatic Polypoidal Choroidal Vasculopathy Completed NCT02821520 Phase 4 conbercept
25 A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of IV Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With PCV. Completed NCT02495181 Phase 4 Intravitreal Aflibercept
26 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
27 SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia Completed NCT03409250 Phase 4 Ranibizumab, Lucentis
28 Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) Completed NCT02320474 Phase 4 Aflibercept
29 The Effects of Low Dose Atropine on Choroidal Thickness Completed NCT03544827 Phase 4 Atropine;Atropine
30 An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
31 Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients Completed NCT00308945 Phase 4 travoprost 0.004% (drug);latanoprost 0.005% (drug)
32 Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise Completed NCT00312416 Phase 4 Clonidin;Brimonidine
33 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
34 A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed NCT01846273 Phase 4 Ranibizumab;Verteporfin PDT;Sham PDT
35 An Open-Label, Multicenter, Phase 4 Study of the Effect of Verteporfin for Injection Therapy in Subjects With Occult With No Classic Choroidal NeoVascularization Secondary to Age-Related Macular Degeneration Completed NCT00135837 Phase 4 Verteporfin for injection
36 A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy as Indicated in Subjects With Polypoidal Choroidal Vasculopathy Completed NCT02120950 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
37 Comparison of Safety, Effectiveness, and Quality-of-life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to AMD Completed NCT01148511 Phase 4 Ranibizumab 0.5 mg
38 Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD) Completed NCT01831947 Phase 4
39 Clinical Research of Photodynamic Therapy for Exudative Age-related Macular Degeneration Accompanied With Polypoidal Choroidal Vasculopathy Completed NCT00331435 Phase 4
40 Choroidal Neovascular Membrane Recurrence Rate in Wet AMD Patients Stable on Three Month Ranibizumab Dosing Completed NCT01453920 Phase 4 Ranibizumab;Ranibizumab
41 Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma Completed NCT03966560 Phase 4 Brimonidine Tartrate;Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops;Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension;Travoprost and Timolol;Bimatoprost and Timolol;Latanoprost
42 The Effect of Oral Contraceptive Pills On Macula, Retinal Nerve Fiber Layer and Choroid Thickness Completed NCT02841202 Phase 4 oral contraceptive pills
43 The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
44 The Influence of Atropine on Choroidal Thickness Completed NCT03158142 Phase 4 Atropine Sulfate 1% Oph Soln
45 Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis Recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
46 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Recruiting NCT02681783 Phase 4 aflibercept
47 Effect of Sodium Glucose co Transporter 2 (SGLT2) Inhibition on Optical Coherence Tomography Angiography (OCT-A) Parameters in Diabetic Chronic Kidney Disease (CKD) Recruiting NCT04215445 Phase 4 Empagliflozin 25 MG
48 Subtenons Triamcinolone Acetonide Injections for Treatment of Persistent Choroidal Effusions Post Glaucoma Surgery Recruiting NCT02917564 Phase 4 Triamcinolone Acetonide 1 ml of 40 mg/mL suspension
49 Evaluation and Comparison of Macular and Choroidal Thickness After Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis Recruiting NCT03363295 Phase 4 Moxifloxacin Injection
50 An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen Active, not recruiting NCT03117634 Phase 4 Treat and Extend with Aflibercept 2mg;Fixed Dosing with Aflibercept 2mg

Search NIH Clinical Center for Posterior Uveitis

Cochrane evidence based reviews: uveitis, posterior

Genetic Tests for Posterior Uveitis

Anatomical Context for Posterior Uveitis

MalaCards organs/tissues related to Posterior Uveitis:

40
Eye, Retina, Endothelial, Liver, Kidney, Bone Marrow, Bone

Publications for Posterior Uveitis

Articles related to Posterior Uveitis:

(show top 50) (show all 1411)
# Title Authors PMID Year
1
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. 61 54
15878055 2005
2
Serum cytokine receptor levels in noninfectious uveitis. 61 54
15746567 2005
3
Human S-antigen: peptide determinant recognition in uveitis patients. 61 54
15010290 2004
4
Human retinal S-antigen: T cell epitope mapping in posterior uveitis patients. 54 61
11263956 2001
5
Oligoclonal activation of CD4+ T lymphocytes in posterior uveitis. 54 61
7882564 1995
6
[Cellular immunoreaction to S-antigen in patients with uveitis and optic neuritis]. 54 61
8223035 1993
7
Identification of an S-antigen-like molecule in human choroid plexus and cerebrospinal fluid. 54 61
1289136 1992
8
Distribution of IL-2R and CD45Ro expression on CD4+ and CD8+ T-lymphocytes in the peripheral blood of patients with posterior uveitis. 61 54
1358556 1992
9
Swept source OCTA reveals a link between choriocapillaris blood flow and vision loss in a case of tubercular serpiginous-like choroiditis. 61
33553805 2021
10
Epidemiology of 2000 Chinese uveitis patients from Northeast China. 61
32424058 2021
11
Optical coherence tomography angiography findings in patients with ocular and non-ocular Behcet disease. 61
33567020 2021
12
Clinical manifestations and visual outcomes associated with ocular toxoplasmosis in a Brazilian population. 61
33542439 2021
13
Epidemiology of Uveitis in a tertiary care centre in Portugal. 61
33593242 2021
14
CRB1-associated retinal dystrophies in a Belgian cohort: genetic characteristics and long-term clinical follow-up. 61
33579689 2021
15
Tubulointerstitial nephritis and uveitis syndrome: a systematic review. 61
33561271 2021
16
Small-molecule antagonist of VLA-4 (GW559090) attenuated neuro-inflammation by targeting Th17 cell trafficking across the blood-retinal barrier in experimental autoimmune uveitis. 61
33602234 2021
17
Frequency and visual outcomes of ocular toxoplasmosis in an adult Brazilian population. 61
33564078 2021
18
The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis. 61
33527798 2021
19
Incidence of ocular inflammation among patients with active tuberculosis or nontuberculous mycobacterial infections in a tertiary hospital in Japan. 61
33475908 2021
20
Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. 61
32358156 2021
21
Etiology of Uveitis in Upper Egypt. 61
33500612 2021
22
Ophthalmic involvement of chronic lymphocytic leukemia: A systematic review of 123 cases. 61
32407752 2021
23
The Role of Plasma Calprotectin in Non-infectious Uveitis. 61
33349072 2021
24
Advances and potential new developments in imaging techniques for posterior uveitis Part 2: invasive imaging methods. 61
32778739 2021
25
A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: Formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study. 61
33516808 2021
26
Advances and potential new developments in imaging techniques for posterior uveitis. Part 1: noninvasive imaging methods. 61
32678354 2021
27
Clinical and laboratory characteristics of ocular syphilis and neurosyphilis among individuals with and without HIV infection. 61
32220852 2021
28
Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review. 61
33065425 2020
29
Uveitis for Dermatologists: A Review. 61
33346521 2020
30
Monthly Intravitreal Infliximab in Behçet's Disease Active Posterior Uveitis: A Long-Term Safety Study. 61
33394998 2020
31
A case of bilateral syphilitic posterior uveitis: Multimodal imaging of the great imitator. 61
32800418 2020
32
Multi-Modal Imaging in Diffuse Subretinal Fibrosis With Uveitis Syndrome. 61
33394959 2020
33
Ocular sarcoidosis: clinical experience and recent pathogenetic and therapeutic advancements. 61
32740881 2020
34
Identifying Mouse Autoimmune Uveitis from Fundus Photographs Using Deep Learning. 61
33294300 2020
35
Beware the quiet eye: primary vitreoretinal lymphoma masquerading as posterior uveitis. 61
33384350 2020
36
Oscillatory potentials in patients with birdshot chorioretinopathy. 61
32542469 2020
37
The first investigation on differences in the effectiveness of mycophenolate mofetil and azathioprine antimetabolites determined in Polish patients treated for non-infectious uveitis. 61
33356073 2020
38
Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let's be ready for a plausible "rebound effect". 61
32960319 2020
39
Recent advances in the management of non-infectious posterior uveitis. 61
32617804 2020
40
Chitosan Oligosaccharides Suppress Nuclear Factor-Kappa B Activation and Ameliorate Experimental Autoimmune Uveoretinitis in Mice. 61
33171990 2020
41
Ocular syphilis 61
33161392 2020
42
Imaging in Tubercular Choroiditis: Current Concepts. 61
32976732 2020
43
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. 61
33157077 2020
44
Mycophenolate sodium in the treatment of corticosteroid-refractory non-infectious inflammatory uveitis (MySTRI study). 61
32632297 2020
45
[Behçet's syndrome : Current diagnostics and treatment]. 61
33052453 2020
46
High-Resolution Imaging of Retinal Vasculitis by Flood Illumination Adaptive Optics Ophthalmoscopy: A Follow-up Study. 61
31573376 2020
47
Quantitative Analysis of the Choriocapillaris in Uveitis Using En Face Swept-Source Optical Coherence Tomography Angiography. 61
32413411 2020
48
Effectiveness of the Dexamethasone Implant in Lieu of Oral Corticosteroids in Intermediate and Posterior Uveitis Requiring Immunosuppression. 61
33021854 2020
49
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program. 61
32564920 2020
50
Early symptomatic neurosyphilis and ocular syphilis: A comparative study between HIV-positive and HIV-negative patients. 61
33239175 2020

Variations for Posterior Uveitis

Expression for Posterior Uveitis

Search GEO for disease gene expression data for Posterior Uveitis.

Pathways for Posterior Uveitis

Pathways related to Posterior Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 TNF LTA IL9 IL6 IL5 IL4
2
Show member pathways
13.95 TNF LTA IL9 IL6 IL5 IL4
3
Show member pathways
13.74 TNF LTA IL9 IL6 IL5 IL4
4
Show member pathways
13.66 TNF LTA IL9 IL6 IL5 IL4
5
Show member pathways
13.52 TNF LTA IL9 IL6 IL5 IL4
6
Show member pathways
13.46 TNF LTA IL9 IL6 IL5 IL4
7
Show member pathways
13.39 TNF LTA IL9 IL6 IL5 IL4
8
Show member pathways
13.27 TNF IL4 IL2RB IL2RA IL2 IL1A
9
Show member pathways
13.05 TNF IL6 IL4 IL2RB IL2RA IL2
10 13 IL6 IL5 IL4 IL2RB IL2RA IL2
11
Show member pathways
12.95 TNF IL6 IL2RB IL2RA IL2 IL1A
12
Show member pathways
12.93 TNF LTA IL9 IL6 IL4 IL2RB
13
Show member pathways
12.92 TNF LTA IL9 IL6 IL5 IL4
14
Show member pathways
12.81 TNF LTA IL9 IL6 IL2 IL1A
15
Show member pathways
12.75 TNF IL9 IL6 IL5 IL4 IL2
16
Show member pathways
12.74 TNF IL4 IL2RA IL2 IFNG ICOSLG
17
Show member pathways
12.71 TNF IL6 IL5 IL4 IL2RB IL2RA
18 12.69 TNF IL4 IL2RB IL2RA IL2 IFNG
19
Show member pathways
12.59 IL5 IL2RA IL2 IL1A IL13 CAPN5
20
Show member pathways
12.55 IL9 IL6 IL5 IL4 IL2RB IL2RA
21
Show member pathways
12.51 TNF LTA IL6 IL2RB IL2RA IL2
22 12.5 TNF LTA IL6 IL2RB IL2RA IL2
23
Show member pathways
12.49 TNF IL6 IL5 IL4 IL13 IFNG
24
Show member pathways
12.44 TNF IL6 IL4 IL2 IFNG
25
Show member pathways
12.43 IL2RB IL2RA IL2 ICOSLG
26
Show member pathways
12.32 TNF IL4 IL1A IFNG
27 12.29 TNF IL6 IL1A IFNG
28
Show member pathways
12.27 TNF LTA IL9 IL6 IL5 IL4
29
Show member pathways
12.25 TNF IL6 IL4 IFNG
30 12.23 TNF IL6 IL1A IL13
31
Show member pathways
12.21 IL5 IL2RB IL2RA IL2
32 12.19 TNF IL6 IL4 IL2 IL1A IFNG
33
Show member pathways
12.18 IL5 IL2RA IL2 IL1A IL13
34
Show member pathways
12.15 IL2RB IL2RA IL2 IFNG
35 12.14 TNF IL6 IL4 IL1A IL13
36
Show member pathways
12.14 IL4 IL2RB IL2RA IL2 IFNG
37 12.12 TNF IL6 IL5 IL4 IL2RB IL2RA
38 12.08 TNF IL6 IL5 IL4 IL2RA IL1A
39 11.98 TNF IL6 IL1A IFNG
40 11.97 IL6 IL5 IL4 IL2 IL13 IFNG
41
Show member pathways
11.93 TNF LTA IL6 IL27 IL2 IFNG
42
Show member pathways
11.93 TNF IL5 IL4 IL2RA IL2 IFNG
43 11.92 IL9 IL4 IL2RB IL2RA IL2
44
Show member pathways
11.89 LTA IL4 IL2RB IL2RA IL2
45 11.88 TNF IL6 IL2 IFNG
46
Show member pathways
11.86 TNF IL6 IL2 IL1A IFNG
47 11.85 TNF IL6 IL5 IL4 IL13
48
Show member pathways
11.83 TNF IL2RB IL2RA IL2 IFNG
49 11.8 TNF IL6 IL1A
50 11.79 TNF LTA IL6 IL5 IL4 IL2RA

GO Terms for Posterior Uveitis

Cellular components related to Posterior Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNF RBP3 LTA IL9 IL6 IL5
2 external side of plasma membrane GO:0009897 9.63 TNF IL2RB IL2RA IL13 ICOSLG CCR6
3 extracellular space GO:0005615 9.44 TNF RBP3 LTA IL9 IL6 IL5
4 interleukin-2 receptor complex GO:0005893 9.26 IL2RB IL2RA

Biological processes related to Posterior Uveitis according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 SAG LTA IL6 IL5 IL4 IL2RB
2 positive regulation of cell proliferation GO:0008284 10.11 IL9 IL6 IL5 IL4 IL2 IFNG
3 positive regulation of gene expression GO:0010628 10.07 TNF IL6 IL4 IL1A IL13 IFNG
4 MAPK cascade GO:0000165 10 TNF IL5 IL2RB IL2RA IL2
5 negative regulation of inflammatory response GO:0050728 9.94 IL4 IL2RA IL2 IL13
6 regulation of insulin secretion GO:0050796 9.87 TNF IL6 IFNG
7 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 TNF IL6 IL13
8 inflammatory response GO:0006954 9.86 TNF IL9 IL6 IL5 IL2RA IL27
9 positive regulation of interleukin-1 beta production GO:0032731 9.85 TNF IL6 IFNG
10 positive regulation of cytokine production GO:0001819 9.85 TNF IL1A IFNG
11 positive regulation of interleukin-6 production GO:0032755 9.85 TNF IL6 IL1A IFNG
12 positive regulation of phagocytosis GO:0050766 9.83 TNF IL2RB IFNG
13 positive regulation of chemokine production GO:0032722 9.82 TNF IL6 IFNG
14 positive regulation of interleukin-10 production GO:0032733 9.82 IL6 IL4 IL13
15 positive regulation of interferon-gamma production GO:0032729 9.8 TNF LTA IL27 IL2
16 positive regulation of JAK-STAT cascade GO:0046427 9.79 TNF IL6 IL5
17 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.78 IL4 IL2 IL1A
18 positive regulation of T cell proliferation GO:0042102 9.78 IL6 IL4 IL2RA IL2
19 positive regulation of activated T cell proliferation GO:0042104 9.76 IL2RA IL2 ICOSLG
20 positive regulation of B cell proliferation GO:0030890 9.73 IL5 IL4 IL2 IL13
21 humoral immune response GO:0006959 9.72 TNF LTA IL6 IFNG CCR6
22 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
23 positive regulation of T cell differentiation GO:0045582 9.71 IL4 IL2RA IL2
24 microglial cell activation GO:0001774 9.71 TNF IL4 IL13 IFNG
25 positive regulation of podosome assembly GO:0071803 9.7 TNF IL5
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 IL4 IFNG
27 negative regulation of T-helper 17 cell differentiation GO:2000320 9.7 IL4 IL2
28 positive regulation of glial cell proliferation GO:0060252 9.7 TNF LTA IL6
29 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL4 IL2
30 positive regulation of mast cell degranulation GO:0043306 9.69 IL4 IL13
31 negative regulation of lipid storage GO:0010888 9.69 TNF IL6
32 regulation of regulatory T cell differentiation GO:0045589 9.69 IL2RA IL2 IFNG
33 vascular endothelial growth factor production GO:0010573 9.68 TNF IL6
34 positive regulation of mononuclear cell migration GO:0071677 9.67 TNF IL4
35 negative regulation of lymphocyte proliferation GO:0050672 9.67 IL2RA IL2
36 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.67 TNF LTA
37 positive regulation of immunoglobulin production GO:0002639 9.67 IL6 IL5 IL2 IL13
38 positive regulation of cellular respiration GO:1901857 9.66 IL4 IFNG
39 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
40 negative regulation of complement-dependent cytotoxicity GO:1903660 9.63 IL4 IL13
41 interleukin-2-mediated signaling pathway GO:0038110 9.63 IL2RB IL2RA IL2
42 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 TNF IL6 IL4 IL2 IL13 IFNG
43 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.62 TNF IFNG
44 regulation of T cell homeostatic proliferation GO:0046013 9.62 IL2RA IL2
45 cytokine-mediated signaling pathway GO:0019221 9.61 TNF IL6 IL5 IL4 IL2RB IL2RA
46 positive regulation of vitamin D biosynthetic process GO:0060557 9.58 TNF IFNG
47 positive regulation of nitrogen compound metabolic process GO:0051173 9.57 TNF IFNG
48 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.56 TNF LTA
49 immune response GO:0006955 9.4 TNF LTA IL9 IL6 IL5 IL4

Molecular functions related to Posterior Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 TNF LTA IL9 IL6 IL5 IL4
2 growth factor activity GO:0008083 9.35 IL9 IL6 IL5 IL4 IL2
3 cytokine receptor binding GO:0005126 9.33 IL9 IL4 IL13
4 interleukin-2 binding GO:0019976 9.32 IL2RB IL2RA
5 interleukin-2 receptor activity GO:0004911 9.26 IL2RB IL2RA

Sources for Posterior Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....